Regulation of nausea and vomiting by cannabinoids

British Journal of Pharmacology

Volumn 163, Issue 7, 2011, Pages 1411-1422

  Parker, Linda A ^a   Rock, Erin M ^a   Limebeer, Cheryl L ^a  

^a UNIVERSITY OF GUELPH   (Canada)

Author keywords

5 hydroxytryptamine; cannabidiol; cannabinoid; conditioned disgust; emesis; gaping; nausea; serotonin; taste reactivity; vomiting

Indexed keywords

1 (2,4 DICHLOROPHENYL) 5 (4 IODOPHENYL) 4 METHYL N (1 PIPERIDYL) 1H PYRAZOLE 3 CARBOXAMIDE; 2 ARACHIDONOYLGLYCEROL; 2 DIPROPYLAMINO 8 HYDROXYTETRALIN; 2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; 4 (1,1 DIMETHYLHEPTYL) 1',2',3',4',5',6' HEXAHYDRO 2,3' DIHYDROXY 6' (3 HYDROXYPROPYL)BIPHENYL; 4 DIPROPYLAMINO 1,3,4,5 TETRAHYDROBENZ[CD]INDOLE 6 CARBOXAMIDE; 5' IODORESINIFERATOXIN; 6 IODO 3 (4 METHOXYBENZOYL) 2 METHYL 1 (2 MORPHOLINOETHYL)INDOLE; ANANDAMIDE; ARVANIL; BUSPIRONE; CANNABIDIOL; CANNABINOID; CISPLATIN; CYCLOHEXYLCARBAMIC ACID 3' CARBAMOYLBIPHENYL 3 YL ESTER; DEXANABINOL; DRONABINOL; ENDOCANNABINOID; INDOMETACIN; LITHIUM CHLORIDE; N (1,4 BENZODIOXAN 6 YL) 3 (4 TERT BUTYLPHENYL)ACRYLAMIDE; NABILONE; ONDANSETRON; PLACEBO; PROCHLORPERAZINE; RIMONABANT; SEROTONIN; SEROTONIN 1A RECEPTOR; SEROTONIN 3 ANTAGONIST; UNINDEXED DRUG; ANTIEMETIC AGENT; CANNABINOID 1 RECEPTOR; CANNABIS; DELTA8 TETRAHYDROCANNABINOL; DIGESTIVE TRACT AGENT; JZL 184; N ARACHIDONOYL DOPAMINE; NABIXIMOLS; PROTEIN C FOS; TETRAHYDROCANNABINOL; UNCLASSIFIED DRUG;

ANTIEMETIC ACTIVITY; CHEMOTHERAPY INDUCED EMESIS; DRUG INHIBITION; ENZYME ACTIVATION; FOREBRAIN; HUMAN; LOW DRUG DOSE; NAUSEA AND VOMITING; NONHUMAN; PRIORITY JOURNAL; RAPHE NUCLEUS; REVIEW; TASTE PREFERENCE; VOMITING; ACUTE DISEASE; ANIMAL BEHAVIOR; ANTICIPATORY NAUSEA AND VOMITING; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; COMPARATIVE EFFECTIVENESS; DOSE RESPONSE; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; EXPERIMENTAL ANIMAL; EXPERIMENTAL MODEL; IRRITABILITY; MOLECULAR INTERACTION; NAUSEA; NEUROPATHIC PAIN; PROTEIN EXPRESSION; SIDE EFFECT; TASTE AVERSION; UNSPECIFIED SIDE EFFECT;

ANIMALS; ANTIEMETICS; CANNABINOIDS; HUMANS; NAUSEA; RECEPTOR, CANNABINOID, CB1; VOMITING;

EID: 79960304851     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2010.01176.x     Document Type: Review

References (152)

1. Aapro MS, Kirchner V, Terrey JP, (1994). The incidence of anticipatory nausea and vomiting after repeat cycle chemotherapy: the effect of granisetron. Br J Cancer 69: 957-960. (Pubitemid 24140683)
2. Aapro MS, Thuerlimann B, Sessa C, De Pree C, Bernhard J, Maibach R, Swiss Group for Clinical Cancer Research (2003). A randomized double-blind trial to compare the clinical efficacy of granisetron with metoclopramide, both combined with dexamethasone in the prophylaxis of chemotherapy-induced delayed emesis. Ann Oncol 14: 291-297. (Pubitemid 36305443)
3. Abrahamov A, Abrahamov A, Mechoulam R, (1995). An efficient new cannabinoid antiemetic in pediatric oncology. Life Sci 56: 2097-2102.
4. Andrews PL, Bhandari P, (1993). Resiniferatoxin, an ultrapotent capsaicin analogue, has anti-emetic properties in the ferret. Neuropharmacology 32: 799-806. (Pubitemid 23227666)
5. Andrews PL, Horn CC, (2006). Signals for nausea and emesis: implications for models diseases. Auton Neurosci 125: 100-115.
6. Andrews PL, Torii Y, Saito H, Matsuki N, (1996). The pharmacology of the emetic response to upper gastrointestinal tract stimulation in Suncus murinus. Eur J Pharmacol 307: 305-313. (Pubitemid 26233372)
7. Andrews PL, Okada F, Woods AJ, Hagiwara H, Kakaimoto S, Toyoda M, et al,. (2000). The emetic and anti-emetic effects of the capsaicin analogue resiniferatoxin in Suncus murinus, the house musk shrew. Br J Pharmacol 130: 1247-1254. (Pubitemid 30488586)
8. Ballatori E, Roila F, (2003). Impact of nausea and vomiting on quality of life in cancer patients during chemotherapy. Health Qual Life Outcomes 1: 46.
9. 3A receptors: probable involvement of an allosteric modulatory site. Br J Pharmacol 137: 589-596. (Pubitemid 35333084)
10. Bartlett N, Koczwara B, (2002). Control of nausea and vomiting after chemotherapy: what is the evidence? Int Med J 32: 401-407. (Pubitemid 36124654)
11. Berger B, (1972). Conditioning of food aversions by injections of psychoactive drugs. J Comp Phys Psychol 81: 21-26.
12. Billig I, Yates BJ, Rinaman L, (2001). Plasma hormone levels and central c-Fos expression in ferrets after systemic administration of cholecystokinin. Am J Physiol Regul Integr Comp Physiol 281: R1243-R1255.
13. Blier P, de Montigny C, (1987). Modification of 5-HT neuron properties by sustained administration of the 5-HT1A agonist gepirone: electrophysiological studies in the rat brain. Synapse 1: 470-480.
14. Borrison HL, Wang SC, (1953). Physiology and pharmacology of vomiting. Pharmacol Rev 5: 193-230.
15. Breslin PA, Spector AC, Grill HJ, (1992). A quantitative comparison of taste reactivity behaviors to sucrose before and after lithium chloride pairings: a unidimensional account of palatability. Behav Neurosci 106: 820-836.
16. Carey MP, Burish TG, Brenner DE, (1983). Delta-9-tetrahydrocannabinol in cancer chemotherapy: research problems and issues. Ann Intern Med 99: 106-114. (Pubitemid 13066666)
17. 1 receptor antagonist reduces weight gain in rat. Am J Physciol Regul Integr Comp Physiol 293: R2185-R2193. (Pubitemid 350224010)
18. Cluny NL, Naylor RJ, Whittle BA, Javid FA, (2008). The effects of cannabidiol and tetrahydrocannabinol on motion-induced emesis in Suncus murinus. Basic Clin Pharmacol Toxicol 103: 150-156. (Pubitemid 352022723)
19. Cluny NL, Chambers AP, Limebeer CL, Keenan CM, Bedard H, Vemuri VK, et al,. (2010). A novel, peripherally resitricted cannabinoid 1 (CB1) receptor antagonist AM6545 recuces food intake and body weight, but does not cause malaise in rodents. Br J Pharmacol 161: 629-642.
20. Coil JD, Hankins WG, Jenden DJ, Garcia J, (1978). The attenuation of a specific cue-to-consequence association by antiemetic agents. Psychopharmacology 56: 21-25. (Pubitemid 8270650)
21. Costall B, Domeney AM, Naylor RJ, Tattersall FD, (1986). 5-Hydroxytryptamine receptor antagonism to prevent cisplatin-induced emesis. Neuropharmacology 25: 959-961. (Pubitemid 16045969)
22. Crawford SM, Buckman R, (1986). Nabilone and metoclopramide in the treatment of nausea and vomiting due to cisplatin: a double blind study. Med Oncol Tumor Pharmacother 3: 39-42. (Pubitemid 16140301)
23. Cristino L, De Petrocellis L, Pryce G, Baker D, Guglielmotti V, DiMarzo V, (2006). immunohistochemical localization of cannabinoid type 1 and vanilloid transient receptor potential vanilloid type 1 receptors in the mouse brain. Neuroscience 139: 1405-1415.
24. Cross-Mellor SK, Ossenkopp KP, Piomelli D, Parker LA, (2007). Effects of the FAAH inhibitor, URB597, and anandamide on lithium-induced taste reactivity responses: a measure of nausea in the rat. Psychopharmacology 190: 135-143. (Pubitemid 46011174)
25. Cunningham D, Bradley CJ, Forrest GJ, Hutcheon AW, Adams L, Sneddon M, et al,. (1988). A randomized trial of oral nabilone and prochlorperazine compared to intravenous metoclopramide and dexamethasone in the treatment of nausea and vomiting induced by chemotherapy regimens containing cisplatin or cisplatin analogues. Eur J Cancer Clin Oncol 24: 685-689. (Pubitemid 18095574)
26. 1 receptor antagonist/inverse agonist SR 141716A. Neuropsychopharmacology 24: 198-203.
27. 1 receptor in the least shrew. Pharmacol Biochem Behav 69: 239-249. (Pubitemid 32566269)
28. 1 receptor antagonist SR 141716A reverses the antiemetic and motor depressant actions of WIN 55, 212-2. Eur J Pharmacol 430: 49-58. (Pubitemid 33042710)
29. Darmani NA, (2002). The potent emetogenic effects of the endocannabinoid, 2-AG (2-arachidonoylglycerol) are blocked by Delta (9)-tetrahydrocannabinol and other cannabinoids. J Pharmacol Exp Ther 300: 34-42. (Pubitemid 34028505)
30. Darmani NA, Johnson CJ, (2004). Central and peripheral mechanisms contribute to the antiemetic actions of delta-9-tetrahydrocannabinol against 5-hydroxytryptophan-induced emesis. Eur J Pharmacol 488: 201-212. (Pubitemid 38388540)
31. 1 receptor antagonist SR 141716A increase brain serotonin and dopamine levels and turnover. Pharmacol Biochem Behav 75: 777-787. (Pubitemid 37289462)
32. Darmani NA, McClanahan BA, Trinh C, Petrosino S, Valenti M, DiMarzo V, (2005). Cisplatin increases brain 2-arachidonoylglycerol (2-AG) and concomitantly reduces intestinal 2-AG and anandamide levels in the least shrew. Neuropharmacology 49: 502-513. (Pubitemid 41169974)
33. Davey VA, Biederman GB, (1998). Conditioned antisickness: indirect evidence from rats and direct evidence from ferrets that conditioning alleviates drug-induced nausea and emesis. J Exp Psychol Anim Behav Process 24: 483-491. (Pubitemid 128737319)
34. deBoer-Dennert M, deWit R, Schmitz I, Djontono J, Beurden V, Stoter G, et al,. (1997). Patient perceptions of the side-effects of chemothareapy: the influence of 5HT3 antagonists. Br J Cancer 76: 1055-1061. (Pubitemid 27434663)
35. Di Marzo V, Fontana A, (1995). Anandamide, an endogenous cannabinomimetic eicosanoid: 'killing two birds with one stone'. Prostaglandins Leukot Essent Fatty Acids 53: 1-11.
36. Di Marzo V, Lastres-Becker I, Bisogno T, DePetrocellis L, Milone A, Davis JB, et al,. (2001). Unsaturated long-chain N-acyl-vanillyl-amides (N-AVAMs): vanilloid receptor ligands that inhibit anandamide-facilitated transport and bind to CB1 cannabinoid receptors. Biochem Biophys Res Commun 262: 275-284. (Pubitemid 29412660)
37. 3 receptors in rat nodose ganglion neurons. J Neurophysiol 73: 907-910.
38. Fegley D, Gaetani S, Duranti A, Tontini A, Mor M, Tarzia G, et al,. (2005). Characterization of the fatty acid amide hydrolase inhibitor cyclohexyl ceramic acid 3′-carbamoyl-biphenyl-3-yl ester (URB597): effects on anandamide and oleoylethanolamide deactivation. J Pharmacol Exp Ther 313: 352-358. (Pubitemid 40411361)
39. Feigenbaum JJ, Richmond SA, Weissman Y, Mechoulam R, (1989). Inhibition of cisplatin-induced emesis in the pigeon by a non-psychotropic synthetic cannabinoid. Eur J Pharmacol 4: 159-165. (Pubitemid 19244960)
40. Ferrari F, Ottanik A, Giuliani D, (1999). Cannabimimetic activity in rats and pigeons of HU-210, a potent antiemetic drug. Pharmacol Biochem Behav 62: 75-80. (Pubitemid 29017758)
41. Gadusek FJ, Kalat JW, (1975). Effects of scopolamine on retention of taste-aversion learning in rats. Physiol Psychol 3: 130-132.
42. Gamzu E, (1977). The multifaceted nature of taste aversion inducing agents: is there a single common factor? In:, Barker L, Domjan M, Best M, (eds). Learning Mechanisms of Food Selection. Baylor Univ. Press: Waco, TX, pp. 447-511.
43. Garcia J, Hankins WG, Rusiniak KW, (1974). Behavioral regulation of the milieu interne in man and rat. Science 185: 824-831.
44. Garcia J, Rusiniak KW, Brett LP, (1977). Conditioning food-illness aversions in wild animals: caveant canonici. In:, Davis H, Hurowitz HMB, (eds). Operant Pavlovian Interactions. Lawrence Erlbaum: Hillsdale: NJ, pp. 273-316.
45. Gorzalka B, Hanson L, Harrington J, Killam S, Campbell-Meiklejohn D, (2003). Conditioned taste aversion: modulation by 5-HT receptor activity and corticosterone. Eur J Pharamcol 47: 129-134. (Pubitemid 36724926)
46. Goudie AJ, Stolerman IP, Demellweek C, D'Mello GD, (1982). Does conditioned nausea mediate drug-induced conditioned taste aversion? Psychopharmacology 78: 277-282.
47. Grelot L, Milano S, LeStunff H, (1995). Does 5-HT play a role in the delayed phase of cisplatin-induced emesis? In:, Reynolds J, Andrews PLR, Davis CJ, (eds). Serotonin and the Scientific Basis of Anti-Emetic Therapy. Oxford Clinical Communications: Oxford, pp. 181-191.
48. Grigson PS, Twining R, (2002). Cocaine-induced suppression of saccharin intake: a model of drug-induced devaluation of natural rewards. Behav Neurosci 116: 321-333. (Pubitemid 34274240)
49. Grill HC, Norgren R, (1978). The taste reactivity test. I. Mimetic responses to gustatory stimuli in neurologically normal rats. Brain Res 143: 263-279. (Pubitemid 8277909)
50. Grinspoon L, Bakalar JB, (1993). Marijuana: The Forbidden Medicine. Yale University Press: New Haven.
51. Gupta YK, Sharma SS, (2002). Involvement of 5-HT1A and 5-HT2 receptor in cisplatin induced emesis in dogs. Indian J Physiol Pharmacol 46: 463-467.
52. Hall W, Christie M, Currow D, (2005). Cannabinoids and cancer: causation, remediation, and palliation. Lancet Oncol 6: 35-42. (Pubitemid 40100410)
53. Hermann H, Marsicano G, Lutz B, (2002). Coexpression of the cannabinoid receptor type 1 with dopamine and serotonin receptors in distinct neuronal subpopulations of the adult mouse forebrain. Neuroscience 109: 541-460.
54. Hermann H, DePetrocellis L, Bisogno T, Schiano-Morello A, Lutz B, DiMarzo V, (2003). Dual effect of cannabinoid CB1 recptor stimulation on a vanniloid VR receptor-mediated response. Cell Mol Life Sci 60: 607-616. (Pubitemid 36459539)
55. Hesketh PJ, Van Belle S, Aapro M, Tattersall FD, Naylor RJ, Hargreaves R, et al,. (2003). Differential involvement of neurotransmitters through the time course of cisplatin-induced emesis as revealed by therapy with specific receptor antagonists. Eur J Cancer 39: 1074-1080. (Pubitemid 36555864)
56. Hickok JT, Roscoe JA, Morrow GR, King DK, Atkins JN, Fitch TR, (2003). Nausea and emesis remain significant problems of chemotherapy despite prophylaxis with 5-hydroxytryptamine-3 antiemetics. Cancer 97: 2880-2886.
57. Hillsley K, Grundy D, (1998). Serotonin and cholecystokinin activate different populations of rat mesenteric vagal afferents. Neurosci Lett 255: 63-66. (Pubitemid 28494199)
58. Himmi T, Dallaporta M, Perrin J, Orsini JC, (1996). Neuronal responses to delta9-tetrahyrocannabinol in the solitary tract nucleus. Eur J Pharmacol 312: 273-279. (Pubitemid 26323509)
59. Himmi T, Perrin J, El Ouazzani T, Orsini JC, (1998). Neuronal responses to cannabinoid receptor ligands in the solitary tract nucleus. Eur J Pharmacol 359: 49-54. (Pubitemid 28515721)
60. Hornby PJ, (2001). Central neurocircuitry associated with emesis. Am J Med 1111: 106S-1112.
61. Howlett AC, Barth F, Bonner TI, Cabral P, Casellaa G, Devane WA, et al,. (2002). International Union of Pharmacology. XXVII. Classification of Cannabinoid Receptors. Pharmacol Rev 54: 161-202. (Pubitemid 34575709)
62. Iversen LL, (2000). The Science of Marijuana. Oxford University Press: New York.
63. 1A receptor agonist, 8-OH-DPAT, on motion-induced emesis in Suncus murinus. Pharmacol Biochem Behav 5: 820-826. (Pubitemid 46149010)
64. Johnson JR, Burnell-Nugent M, Lossignol D, Ganae-Motan ED, Potts R, Fallon MT, (2010). Multicenter, double-blind, randomized, placebo controlled, parallel-group study of the efficacy, safety, and tolerability of THC:CBD Extract and THC extract in patients with intractable cancer-related pain. J Pain Symptom Manage 39: 167-179.
65. Jordan K, Kasper C, Schmoll HJ, (2005). Chemotherapy-induced nausea and vomiting: current and new standards in the antiemetic prophylaxis and treatment. Eur J Cancer 41: 199-205. (Pubitemid 40126951)
66. Kimura T, Ohta T, Watanabe K, Yoshimura H, Yamamoto I, (1998). Anandamide, an endogenous cannabinoid receptor ligand, also interacts with 5-hydroxytryptamine (5HT) receptor. Biol Pharm Bull 21: 224-226. (Pubitemid 28166906)
67. Kwiatkowska M, Parker LA, Burton P, Mechoulam R, (2004). A comparative analysis of the potential of cannabinoids and ondansetron to suppress cisplatin-induced emesis in the Suncus murinus (house musk shrew). Psychopharmacology 174: 254-259. (Pubitemid 38916299)
68. Layeeque R, Siegel E, Kass R, Henry-Tillman RS, Colvert M, Mancino A, et al,. (2006). Prevention of nausea and vomiting following breast surgery. Am J Surg 191: 767-772. (Pubitemid 43744504)
69. Limebeer CL, Parker LA, (1999). Delta-9-tetrahydrocannabinol interferes with the establishment and the expression of conditioned disgust reactions produced by cyclophosphamide: a rat model of nausea. Neuroreport 26: 371-384.
70. Limebeer CL, Parker LA, (2000). Ondansetron interferes with the establishment and the expression of conditioned disgust reactions: a rat model of nausea. J Exp Psychol Anim Behav Process 26: 371-384.
71. 1A agonist 8-OH-DPAT dose-dependently interferes with the establishment and the expression of lithium-induced conditioned rejection reactions in rats. Psychopharmacology 166: 120-126. (Pubitemid 36313118)
72. Limebeer CL, Parker LA, Fletcher P, (2004). 5,7-dihydroxytryptamine lesions of the dorsal and median raphe nuclei interfere with lithium-induced conditioned gaping, but not conditioned taste avoidance, in rats. Behav Neurosci 118: 1391-1399. (Pubitemid 39578485)
73. Limebeer CL, Hall G, Parker LA, (2006). Exposure to a lithium-paired context elicits gaping in rats: a model of anticipatory nausea. Physiol Behav 88: 398-403. (Pubitemid 44093613)
74. Limebeer CL, Krohn JP, Rock EM, Cross-Mellor SK, Parker LA, Ossenkopp KP, (2008). Exposure to a context previously associated with toxin(LiCl)- or motion-induced sickness elicits conditioned gaping in rats: evidence in support of a model of anticipatory nausea. Behav Brain Res 187: 33-40. (Pubitemid 350216188)
75. Limebeer CL, Vemuri VK, Bedard H, Lang ST, Ossenkopp KP, Makriyannis A, et al,. (2010). Inverse agonism of CB1 recpotrs potentiates LiCl-induced nausea: evidence from the conditioned gaping model in rats. Br J Pharmacol 161: 336-349.
76. Long JZ, Li W, Booker L, Burston JJ, Kinsey SG, Schlosburg JE, et al,. (2009a). Selective blockade of 2-arachidonoylglycerol hydrolysis produces cannabinoid behavioural effects. Nat Chem Biol 5: 37-44.
77. Long JZ, Nomura DK, Cravatt BF, (2009b). Characterization of Monoacylglycerol lipase inhibition reveals differences in central and peripheral endocannabinoid metabolism. Chem Biol 16: 744-753.
78. Lucot JB, (1990). Effects of serotonin antagonists on motion sickness and its suppression by 8-OH-DPAT in cats. Pharmacol Biochem Behav 37: 283-287. (Pubitemid 20339381)
79. Lucot JB, Crampton GH, (1989). 8-OH DPAT suppresses vomiting in the cat elicited by motion, cisplatin, or xylazine. Pharmacol Biochem Behav 33: 627-631. (Pubitemid 19237539)
80. McCarthy LE, Borison HL, (1981). Anti-emetic activity of N-methyllevonantrobil and naboline in cisplatin treated cats. J Clin Pharmacol 21: 30S-37S.
81. McLaughlin PJ, Winston KM, Limebeer CL, Parker LA, Makriyannis A, Salamone JD, (2005). The cannabinoid antagonist AM 251 produces food avoidance and behaviors associated with nausea but does not impair feeding efficiency in rats. Psychopharmacology 180: 286-293. (Pubitemid 40909674)
82. Matsuki N, Ueno S, Kaji T, Ishihara A, Wang CH, Saito H, (1988). Emesis induced by cancer chemotherapeutic agents in the Suncus murinus: a new experimental model. Jpn J Pharmacol 48: 303-306.
83. Meachum CL, Bernstein IL, (1992). Behavioral conditioned responses to contextual and odor stimuli paired with LiCl administration. Physiol Behav 52: 895-899.
84. Mechoulam R, (2005). Plant cannabinoids: a neglected pharmacological treasure trove. Br J Pharmacol 146: 913-915. (Pubitemid 41722162)
85. Mechoulam R, Parker LA, Gallily R, (2002). Cannabidiol: an overview of some pharmacological aspects. J Clin Pharmacol 42: 11S-19S. (Pubitemid 35205041)
86. Meiri E, Jhangiani H, Vredenburgh JJ, Barbato LM, Carter FJ, Yang HM, et al,. (2007). Efficacy of dronabinol alone and in combination with ondansetron versus ondansetron alone for delayed chemotherapy-induced nausea and vomiting. Curr Med Res Opin 23: 533-543. (Pubitemid 46456901)
87. Miner WJ, Sanger GJ, (1986). Inhibition of cisplatin-induced vomiting by selective 5-hydroxytryptamine M-receptor antagonism. Br J Pharmacol 88: 497-499. (Pubitemid 16066912)
88. Morrow GR, Dobkin PL, (1988). Anticipatory nausea and vomiting in cancer patients undergoing chemotherapy treatment: prevalence, etiology and behavioral interventions. Clin Psychol Rev 8: 517-556. (Pubitemid 18266336)
89. Nesse RM, Carli T, Curtis GC, Kleinman PD, (1980). Pretreatment nausea in cancer chemotherapy: a conditioned response? Psychosom Med 42: 33-36. (Pubitemid 10084799)
90. Okada F, Torii Y, Saito H, Matsuki N, (1994). Antiemetic effects of serotonergic 5-HT1A-receptor agonists in Suncus murinus. Jpn J Pharmacol 64: 109-114. (Pubitemid 24091838)
91. Parker LA, (1982). Nonconsummatory and consummatory behavioral CRs elicited by lithium-paired and amphetamine-paired flavors. Learn Motiv 13: 281-303.
92. Parker LA, (1995). Rewarding drugs produce taste avoidance, but not taste aversion. Neurosci Biobehav Rev 19: 143-151.
93. Parker LA, (1998). Emetic drugs produce conditioned rejection reactions in the taste reactivity test. J Psychophysiol 12: 3-13. (Pubitemid 28386586)
94. Parker LA, (2003). Taste avoidance and taste aversion: evidence for two different processes. Learn Behav 31: 165-172. (Pubitemid 37243119)
95. Parker LA, Kemp S, (2001). Tetrahydrocannabinol (THC) interferes with conditioned retching in Suncus murinus: an animal model of anticipatory nausea and vomiting (ANV). Neuroreport 12: 749-751. (Pubitemid 32222711)
96. Parker LA, Limebeer CL, (2008). Cannabinoids in the management of nausea and vomiting. In:, Kofalvi A, (ed.). Cannabinoids and the Brain. Springer-Verlag Press: New York.
97. Parker LA, McLeod KB, (1991). Chin rub CRs may reflect conditioned sickness elicited by a lithium-paired sucrose solution. Pharmacol Biochem Behav 40: 983-986.
98. Parker LA, Mechoulam R, (2003). Cannabinoid agonists and an antagonist modulate conditioned gaping in rats. Integr Physiol Behav Sci 38: 134-146.
99. Parker LA, Corrick ML, Limebeer CL, Kwiatkowska M, (2002a). Amphetamine and morphine produce a conditioned taste and place preference in the house musk shrew (Suncus murinus). J Exp Psychol Anim Behav Process 28: 75-82. (Pubitemid 44220060)
100. Parker LA, Mechoulam R, Schlievert C, (2002b). Cannabidiol, a non-psychoactive component of cannabis, and its dimethylheptyl homolg suppress nausea in an experimental model with rats. Neuroreport 13: 567-570. (Pubitemid 34293468)
101. Parker LA, Mechoulam R, Shlievert C, Abbott L, Fudge ML, Burton P, (2003). Effects of cannabinoids on lithium-induced conditioned rejection reactions in a rat model of nausea. Psychopharmacology 166: 156-162. (Pubitemid 36313122)
102. Parker LA, Kwiatkowska M, Burton P, Mechoulam R, (2004). Effect of cannabinoids on lithium-induced vomiting in the Suncus murinus. Psychopharmacology 171: 156-161. (Pubitemid 38134652)
103. Parker LA, Limebeer CL, Kwiatkowska M, (2005). Cannabinoids: effects on vomiting and nausea in animal model. In:, Mechoulam R, (ed.). Cannabinoids As Therapeutics. Birkhauser Verlag, Basel: Switzerland, pp. 183-200.
104. Parker LA, Kwiatkowska M, Mechoulam R, (2006). Delta-9- tetrahydrocannabinol and cannabidiol, but not ondansetron, interfere with conditioned retching reactions elicited by a lithium-paired context in Suncus murinus: an animal model of anticipatory nausea and vomiting. Physiol Behav 87: 61-71.
105. Parker LA, Rana SA, Limebeer CL, (2008). Conditioned disgust, but not conditioned taste avoidance: a measure of conditioned nausea in rats. Can J Exp Psychol 6: 198-209.
106. Parker LA, Limebeer CL, Rock EM, Litt DL, Kwiatkowska M, and Piomelli D, (2009a). The FAAH inhibitor URB-597 interferes with cisplatin- and nicotine- induced vomiting in the Suncus murinus (house musk shrew). Physiol Behav 97: 121-124.
107. Parker LA, Limebeer CL, Rana SA, (2009b). Conditioned disgust, but not conditioned taste avoidance, may reflect conditioned nausea in rats. In:, Reilly S, Schachtman TR, (eds). Conditioned Taste Aversions: Behavioral and Neural Processes. Oxford University Press: NY.
108. Pavlov IP, (1927). Conditioned Reflexes. (G.V. anrep, trans.). Oxford University Press: London, England.
109. Pertwee RG, (2001). Cannabinoids and the gastrointestinal tract. Gut 48: 859-867. (Pubitemid 32476991)
110. Pertwee RG, (2004). The Pharmacology and Therapeutic Potential of Cannabidiol., DiMarzo V, (ed.) Kluver Academic/Plenum Publishers: Cannabinoids.
111. Pertwee RG, (2009). Emerging strategies for exploiting cannabinoid receptor agonists as medicines. Br J Pharmacol 156: 397-411.
112. Pi-Sunyer FX, Aronne LJ, Heshmati HM, Devin J, Rosenstock J, RIO-North American Study Group (2006). Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients. JAMA 295: 761-775. (Pubitemid 43244304)
113. Rabin BM, Hunt WA, (1983). Effects of anti-emetics on the acquisition and recall of radiation and lithium chloride induced conditioned taste aversions. Pharmacol Biochem Behav 18: 629-636.
114. 3 receptors in vivo. Eur J Pharmacol 596: 98-101.
115. Randall PA, Vemuri VK, Segovia KN, Torres EF, Hosmer S, Nunes EJ, et al,. (2010). The novel cannabinoid CB1 antagonists AM6545 suppresses food intake and food-reinforced behavior. Pharmacol Biochem Behav 97: 179-184.
116. 9- tetrahydrocannabinol suppresses vomiting behavior and Fos expression in both acute and delayed phases of cisplatin-induced emesis in the least shrew. Behav Brain Res 196: 30-36.
117. Reicher MA, Holman EW, (1977). Location preference and flavor aversion reinforced by amphetamine in rats. Anim Learn Behav 5: 343-346. (Pubitemid 8237422)
118. Reynolds DJM, Barber NA, Grahame-Smith DG, Leslie RA, (1991). Cisplatin-evoked induction of c-fos protein in the brainstem of the ferret: the effect of cervical vagotomy and the antiemetic 5HT-3 receptor antagonist granisetron. Brain Res 565: 321-336.
119. Rock EM, Limebeer CL, Mechoulam R, Piomelli D, Parker LA, (2008). The effect of cannabidiol and URB597 on conditioned gaping (a model of nausea) elicited by a lithium-paired context in the rat. Psychopharmacol 196: 389-395.
120. 1A auto-receptor agonist to reduce toxin-induced nausea and vomiting. Poster presented at the Society for Neuroscience meeting, San Diego: CA.
121. Rudd JA, Naylor RJ, (1996). An interaction of ondansetron and dexamethasone antagonizing cisplatin-induced acute and delayed emesis in the ferret. Br J Pharmacol 118: 209-214. (Pubitemid 26149263)
122. 1 tachykinin receptor antagonist, CP 99,994, in antagonizing the acute and delayed emesis induced by cisplatin in the ferret. Br J Pharmacol 119: 931-936. (Pubitemid 26366488)
123. 3 receptors are not involved in conditioned taste aversions induced by 5-hydroxytryptamine, ipecacuanha or cisplatin. Eur J Pharmacol 352: 143-149. (Pubitemid 28345111)
124. Russo EB, Burnett A, Hall B, Parker KK, (2005). Agonist properties of cannabidiol at 5-HT1a receptors. Neurochem Res 30: 1037-1043. (Pubitemid 41570039)
125. Schlicker E, Kathmann M, (2001). Modulation of transmitter release via presynaptic cannabinoid receptors. Trends Pharmacol Sci 22: 571-572.
126. Sharkey KA, Cristino L, Oland LD, Van Sickle MD, Starowicz K, Pittman QJ, et al,. (2007). Arvanil, anandamide and N-arachidonolyl-dopamine (NADA) inhibit emesis through cannabinoid CB1 and vanilloid TRPV1 receptors in the ferret. Eur J Neurosci 25: 2773-2782. (Pubitemid 46888837)
127. Simoneau II, Hamza MS, Mata HP, Siegel EM, Vanderah TW, Porreca F, et al,. (2001). The cannabinoid agonist WIN 55,212-2 suppresses opioid-induced emesis in ferrets. Anesthesiology 94: 882-886.
128. 1 receptor neutral antagonist AM4113 suppresses food intake and food-reinforced behavior but does not induce signs of nausea in rats. Neuropsychopharmacology 33: 1-10.
129. Slatkin NE, (2007). Cannabinoids in the treatment of chemotherapy-induced nausea and vomiting: beyond prevention of acute emesis. J Support Oncol 5S: 1-9.
130. Sticht MA, Long JZ, Rock EM, Limebeer CL, Mechoulam R, Cravatt BJ, et al,. (2010). Effect of MAGL inhibitor, JZL184, on LiCl-induced emesis in the Suncus murinus and 2-AG on LiCl-induced conditioned gaping (a model of nausea) in rats. Poster presented at the Society for Neuroscience, San Diego: CA.
131. Stockhorst U, Klosterhalfen S, Klosterhalfen W, Winkelmann M, Steingrueber HJ, (1993). Anticipatory nausea in cancer patients receiving chemotherapy: classical conditioning etiology and therapeutical implications. Integr Physiol Behav Sci 28: 177-181.
132. Tam J, Vemuri VK, Liu J, Batkai S, Mukhopadhyay B, Godlewski G, et al,. (2010). Peripheral CB1 cannabinoid receptor blockade improves cardiometabolic risk in mouse models of obesity. J Clin Invest 120: 2953-2966.
133. 3 receptor antagonists in Suncus Murinus. Jpn J Pharmacol 55: 107-113.
134. Tramer MR, Carroll D, Campbell FA, Reynolds DJM, Moore RA, McQuay HJ, (2001). Cannabinoids for control of chemotherapy induced nausea and vomiting: quantitative systematic review. BMJ 323: 1-8.
135. Travers JB, Norgren R, (1986). Electromyographic analysis of the ingestion and rejection of sapid stimuli in the rat. Behav Neurosci 100: 544-555. (Pubitemid 17169566)
136. Tsukada H, Hirose T, Yokoyama A, Kurita Y, (2001). Randomized comparison of ondansetron plus dexamethasone with desamethasone alone for the control of delayed cisplatin-induced emesis. Eur J Cancer 37: 2398-2404. (Pubitemid 33097477)
137. Tuerke KJ, Limebeer CL, Lester J, Chambers J, Fletcher PJ, Parker LA, (2010). Depletion of serotonin in the insular cortex by 5,7-Dihydroxytrptamine (5,7-DHT) lesions attenuates conditioned nauea in rats. Poster presented at the Society for Neuroscience meetings, San Diego.
138. Ueno S, Matsuki N, Saito H, (1987). Suncus murinus: a new experimental model in emesis research. Life Sci 43: 513-518. (Pubitemid 17105232)
139. Ungerleider JT, Andrysiak TA, Fairbanks LA, Tesler AS, Parker RG, (1984). Tetrahydrocannabinol vs. prochlorperazine. The effects of two antiemetics on patients undergoing radiotherapy. Radiology 150: 598-599. (Pubitemid 14224608)
140. Van Belle S, Lichinitser M, Navari R, Garin AM, Decramer ML, Riviere A, et al,. (2002). Prevention of cisplatin-induced acute and delayed emesis by the selective neurokinin-1 antagonists, L-758,298 and MK869. Cancer 94: 3032-3041. (Pubitemid 34547705)
141. Van der Stelt M, DiMarzo V, (2004). Endovanilloids. Putative endogenous ligands of transient receptor potential vanilloid 1 channels. Eur J Biochem 271: 1827-1834. (Pubitemid 38657337)
142. Van Sickle MD, Oland LD, HO W, Hillard CJ, Mackie K, Davison JS, et al,. (2001). Cannabinoids inhibit emesis through CB1 receptors in the brainstem of the ferret. Gastroenterology 121: 767-774. (Pubitemid 32959386)
143. 1 receptors in specific regions of dorsal vagal complex to inhibit emesis in ferrets. Am J Physiol Gastrointest Liver Physiol 285: G566-G576. (Pubitemid 37021816)
144. 2 receptors. Science 310: 329-332. (Pubitemid 41457202)
145. 9-tetrahydrocannabinol when combined with tropisetron or dexamethasone in the least shrew. Pharmacol Biochem Behav 91: 367-373.
146. Wegener G, Smith DF, Rosenberg R, (1997). 5-HT1A receptors in lithium-induced conditioned taste aversion. Psychopharmacol 133: 51-54. (Pubitemid 27395819)
147. Wise R, Yokel P, DeWit H, (1976). Both positive reinforcement and conditioned aversion from amphetamine and from apomorphine in rats. Science 191: 1273-1274.
148. Wolff MC, Leander JD, (1994). Antiemetic effects of 5-HT1A agonists in the pigeon. Pharmacol Biochem Behav 49: 385-391.
149. 3 antagonists in the pigeon. Pharmacol Biochem Behav 52: 571-575.
150. 1A receptor agonist on acute and delayed cyclophosphamide-induced vomiting. Eur J Pharmacol 340: 217-220. (Pubitemid 28022645)
151. Yamakuni H, Sawai-Nakayama H, Imazumi K, Maeda Y, Matsuo M, Manda T, et al,. (2002). Resiniferatoxin antagonizes cisplatin-induced emesis in dogs and ferrets. Eur J Pharmacol 442: 273-278. (Pubitemid 34626203)
152. 3A receptor-mediated currents in Xenopus laevis Oocytes. J Pharmacol Exp Therap 333: 547-554. (Pubitemid 350005116)